Entero to acquire 80% in Bioaide and 51% in Anand Chemiceutics
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.8 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved acquiring 80% stake in Bioaide Technologies (Delhi) for INR 31.13 to 36 Crore in cash, to close by Feb 15, 2026. Also approved 51% stake in Anand Chemiceutics (Pune) for INR 210 to 230 Crore cash via slump sale, subject to due diligence. Both firms distribute medical devices, aligning with Entero's core business. Bioaide FY25 revenue about INR 55.8 Crore; Anand group FY25 revenue about INR 474.9 Crore.
Two bolt-on acquisitions strengthen Entero's medical device distribution network. Combined cost up to about INR 266 Crore in cash, likely funded internally.